对于1型自体主导性低血症 (ADH1) 的quinazolinone calcilytic治疗的特征
Fadil M Hannan1, Kreepa G Kooblall2, Mark Stevenson2
1Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, UK.
基纳索林卡西利特类药物,如AXT914,在治疗1型自体主导性低血症 (ADH1) 方面表现有前途. 这些化合物有效地使水平正常化,并在ADH1.1的临床前模型中增加副甲状腺激素.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 感受受体 (CaSR) 的功能获取突变会导致1型自体主导性低血症 (ADH1).
- ADH1可能导致症状性低血症和低副甲状腺激素水平.
- 目前对ADH1的治疗方法有限,需要新的治疗策略.
研究的目的:
- 为了评估quinazolinone calcilytics (ATF936和AXT914) 作为潜在的治疗ADH1.
- 为了比较quinazolinone calcilytics与现有的氨基醇 calcilytics的疗效.
主要方法:
- 使用CaSR冷-EM结构进行了性对接研究.
- 在体外剂量反应研究中使用了表达CaSR的HEK293细胞.
- 在体内进行的研究中,小鼠具有功能增益的CaSR突变 (Leu723Gln).
主要成果:
- ATF936和AXT914结合到CaSR跨膜域内的一个共同区域,一个ADH1突变热点.
- 在表达Nuf突变CaSR的细胞中,AXT914正常化了CaSR的功能增长,在10nM.
- 在Nuf小鼠中,口服AXT914显著增加了副甲状腺激素和血水平.
结论:
- 基纳索林卡西利基显示出作为针对ADH1.1的向治疗的潜力.
- 在临床前模型中,AXT914有效地逆转了CaSR的功能增长,并纠正了低血症.
- 需要进一步研究用于ADH1治疗的quinazolinone calcilytics.
更多相关视频
07:13Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation
Published on: March 14, 2017
08:02Author Spotlight: Enhanced Quantification of Cardiovascular Calcification Progression for Longitudinal Micro PET/CT Studies in Small Research Animals
Published on: November 15, 2024
相关概念视频
Skeleton and Calcium Homeostasis
Antihypertensive Drugs: Thiazide-Class Diuretics
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Antihypertensive Drugs: Action of Calcium Channel Blockers
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
